Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

NCT00798707 | Completed Phase 3 Results

• 3 other identifiers: 3151A1-3359B20610033151A1-3359-WW
• Study Type: interventional
• Target: 709
• Locations: 2 countries
• Sites: 78

Brief Summary

The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.

Conditions

Major Depressive Disorder

Keywords

Major Depressive Disorder

Outcome Measures

Primary Outcomes (1)

• Change From Baseline in HAM-D17 Total Score at the Final On-therapy (FOT)Evaluation (Week 8 or ET)

  HAM-D17: a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.

  Baseline and Week 8 (or ET)

Secondary Outcomes (8)

• Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) at FOT Evaluation (Week 8 or ET)

  Week 8 (or ET)

• Change From Baseline in Mean CGI-S Score at FOT Evaluation (Week 8 or ET)

  Baseline and Week 8 (or ET)

• Change From Baseline in MADRS Total Score at FOT Evaluation (Week 8 or ET)

  Baseline and Week 8 (or ET)

• Change From Baseline in HAM-D6 Total Score at FOT Evaluation (Week 8 or ET)

  Baseline and Week 8 (or ET)

• Number of Participants With a Response on the HAM-D17 at FOT Evaluation (Week 8 or ET)

  Week 8 (or ET)

Other Outcomes (6)

• Population Pharmacokinetics for Desvenlafaxine Plasma Concentrations

  Week 2, 4 and 8 (or ET)

• Change From Baseline in SDS at FOT Evaluation (Week 8 or ET)

  Baseline and Week 8 (or ET)

• Change From Baseline in WHO-5 Total Score at FOT Evaluation (Week 8 or ET)

  Baseline and Week 8 (or ET)

Study Arms (3)

Desvenlafaxine succinate sustained-release 25 mg

EXPERIMENTAL

Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)

Desvenlafaxine succinate sustained-release 50 mg

EXPERIMENTAL

Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)

Placebo

PLACEBO COMPARATOR

Drug: placebo

Interventions

Desvenlafaxine Succinate Sustained-Release (DVS SR) DRUG

25 mg tablet, once daily dosing for 8 weeks

Desvenlafaxine succinate sustained-release 25 mg

placebo DRUG

Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening)
• Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of \>= 20
• Clinical Global Impressions Scale-Severity (CGI-S) score of \>= 4

You may not qualify if:

• Clinical instability - 25% or greater increase/decrease in HAM-D 17 total score from screening to baseline
• Significant risk of suicide as assessed by clinician judgement, HAM-D 17 and Columbia Suicide-Severity Rating Scale scores Other eligibility criteria also apply

Sponsors & Collaborators

• Pfizer: lead

Study Sites (78)

Pfizer Investigational Site

Arcadia, California, 91007, United States

Location

Pfizer Investigational Site

Beverly Hills, California, 90210, United States

Location

Pfizer Investigational Site

Cerritos, California, 90703, United States

Location

Pfizer Investigational Site

Garden Grove, California, 92845, United States

Location

Pfizer Investigational Site

Los Alamitos, California, 90720, United States

Location

Pfizer Investigational Site

St. Petersburg, Florida, 33702, United States

Location

Pfizer Investigational Site

Atlanta, Georgia, 30328, United States

Location

Pfizer Investigational Site

Smyrna, Georgia, 30080, United States

Location

Pfizer Investigational Site

Libertyville, Illinois, 60048, United States

Location

Pfizer Investigational Site

Dayton, Ohio, 45408, United States

Location

Pfizer Investigational Site

East Providence, Rhode Island, 02914, United States

Location

Pfizer Investigational Site

Columbia, South Carolina, 29201, United States

Location

Pfizer Investigational Site

Memphis, Tennessee, 38117, United States

Location

Pfizer Investigational Site

Dallas, Texas, 75230, United States

Location

Pfizer Investigational Site

San Antonio, Texas, 78229, United States

Location

Pfizer Investigational Site

Salt Lake City, Utah, 84107, United States

Location

Pfizer Investigational Site

Kirkland, Washington, 98033, United States

Location

Pfizer Investigational Site

Seattle, Washington, 98104, United States

Location

Pfizer Investigational Site

Brown Deer, Wisconsin, 53223, United States

Location

Pfizer Investigational Site

Nagoya, Aichi-ken, 4530015, Japan

Location

Pfizer Investigational Site

Toyoake, Aichi-ken, 4701192, Japan

Location

Pfizer Investigational Site

Noda, Chiba, 2780033, Japan

Location

Pfizer Investigational Site

Fukuoka, Fukuoka, 8100001, Japan

Location

Pfizer Investigational Site

Fukuoka, Fukuoka, 8100041, Japan

Location

Pfizer Investigational Site

Kitakyushu, Fukuoka, 8020006, Japan

Location

Pfizer Investigational Site

Kitakyushu, Fukuoka, 8078555, Japan

Location

Pfizer Investigational Site

Fukushima, Fukushima, 9600102, Japan

Location

Pfizer Investigational Site

Shirakawa, Fukushima, 9610021, Japan

Location

Pfizer Investigational Site

Fujioka, Gunma, 3750017, Japan

Location

Pfizer Investigational Site

Kumagaya, Gunma, 3600032, Japan

Location

Pfizer Investigational Site

Hatsukaichi, Hiroshima, 7380023, Japan

Location

Pfizer Investigational Site

Hiroshima, Hiroshima, 7310121, Japan

Location

Pfizer Investigational Site

Kure, Hiroshima, 7370023, Japan

Location

Pfizer Investigational Site

Sapporo, Hokkaido, 0028029, Japan

Location

Pfizer Investigational Site

Sapporo, Hokkaido, 0040052, Japan

Location

Pfizer Investigational Site

Sapporo, Hokkaido, 0600061, Japan

Location

Pfizer Investigational Site

Sapporo, Hokkaido, 600042, Japan

Location

Pfizer Investigational Site

Sapporo, Hokkaido, 630061, Japan

Location

Pfizer Investigational Site

Sapporo, Hokkaido, 630804, Japan

Location

Pfizer Investigational Site

Kobe, Hyōgo, 6530841, Japan

Location

Pfizer Investigational Site

Kanazawa, Ishikawa-ken, 9208650, Japan

Location

Pfizer Investigational Site

Minamiashigara, Kanagawa, 2500136, Japan

Location

Pfizer Investigational Site

Yokohama, Kanagawa, 2200004, Japan

Location

Pfizer Investigational Site

Yokohama, Kanagawa, 2210835, Japan

Location

Pfizer Investigational Site

Yokohama, Kanagawa, 2250012, Japan

Location

Pfizer Investigational Site

Kumamoto, Kumamoto, 8618002, Japan

Location

Pfizer Investigational Site

Kumamoto, Kumamoto, 8620909, Japan

Location

Pfizer Investigational Site

Yatsushiro, Kumamoto, 8660043, Japan

Location

Pfizer Investigational Site

Kyoto, Kyoto, 6168421, Japan

Location

Pfizer Investigational Site

Matsumoto, Nagano, 3908510, Japan

Location

Pfizer Investigational Site

Osaka, Osaka, 5420006, Japan

Location

Pfizer Investigational Site

Sakai, Osaka, 5900018, Japan

Location

Pfizer Investigational Site

Kanzaka, Saga-ken, 8420192, Japan

Location

Pfizer Investigational Site

Misato, Saitama, Saitama, 3410018, Japan

Location

Pfizer Investigational Site

Saitama, Saitama, 33000062, Japan

Location

Pfizer Investigational Site

Saitama, Saitama, 3390057, Japan

Location

Pfizer Investigational Site

Kusatsu, Shiga, 5250037, Japan

Location

Pfizer Investigational Site

Bunkyo, Tokyo, 1120012, Japan

Location

Pfizer Investigational Site

Chiyoda City, Tokyo, 1000006, Japan

Location

Pfizer Investigational Site

Chiyoda City, Tokyo, 1018643, Japan

Location

Pfizer Investigational Site

Katsushika-ku, Tokyo, 1250041, Japan

Location

Pfizer Investigational Site

Kodaira, Tokyo, 1858551, Japan

Location

Pfizer Investigational Site

Minato, Tokyo, 1070052, Japan

Location

Pfizer Investigational Site

Nakano City, Tokyo, 1640012, Japan

Location

Pfizer Investigational Site

Setagaya City, Tokyo, 1540012, Japan

Location

Pfizer Investigational Site

Setagaya-ku, Tokyo, 1540004, Japan

Location

Pfizer Investigational Site

Shibuya City, Tokyo, 1500001, Japan

Location

Pfizer Investigational Site

Shibuya City, Tokyo, 1510053, Japan

Location

Pfizer Investigational Site

Shinagawa, Tokyo, 1410021, Japan

Location

Pfizer Investigational Site

Shinagawa, Tokyo, 1410022, Japan

Location

Pfizer Investigational Site

Shinagawa, Tokyo, 1420021, Japan

Location

Pfizer Investigational Site

Shinjyuku, Tokyo, 1600023, Japan

Location

Pfizer Investigational Site

Suginami, Tokyo, 1660003, Japan

Location

Pfizer Investigational Site

tabashi City, Tokyo, 1730004, Japan

Location

Pfizer Investigational Site

Taitō City, Tokyo, 1100003, Japan

Location

Pfizer Investigational Site

Toshima City, Tokyo, 1700002, Japan

Location

Pfizer Investigational Site

Meguro City, Toyko, 1520012, Japan

Location

Pfizer Investigational Site

Ube, Yamaguchi, 7558505, Japan

Location

Related Publications (6)

• Zilcha-Mano S, Wang X, Wajsbrot DB, Boucher M, Fine SA, Rutherford BR. Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression. J Clin Psychopharmacol. 2021 Sep-Oct 01;41(5):579-584. doi: 10.1097/JCP.0000000000001435.

  PMID: 34183490 DERIVED

• Soares CN, Zhang M, Boucher M. Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine. CNS Spectr. 2019 Jun;24(3):322-332. doi: 10.1017/S1092852917000633. Epub 2017 Nov 15.

  PMID: 29140227 DERIVED

• McIntyre RS, Fayyad R, Mackell JA, Boucher M. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder. Curr Med Res Opin. 2016;32(3):587-99. doi: 10.1185/03007995.2015.1136603. Epub 2016 Jan 13.

  PMID: 26709542 DERIVED

• McIntyre RS, Fayyad RS, Guico-Pabia CJ, Boucher M. A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d. Prim Care Companion CNS Disord. 2015 Jun 4;17(3):10.4088/PCC.14m01741. doi: 10.4088/PCC.14m01741. eCollection 2015.

  PMID: 26644956 DERIVED

• Thase ME, Fayyad R, Cheng RF, Guico-Pabia CJ, Sporn J, Boucher M, Tourian KA. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis. Curr Med Res Opin. 2015 Apr;31(4):809-20. doi: 10.1185/03007995.2015.1020365. Epub 2015 Mar 26.

  PMID: 25758058 DERIVED

• Iwata N, Tourian KA, Hwang E, Mele L, Vialet C. Efficacy and safety of desvenlafaxine 25 and 5050% shaded blockmg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013 Jan;19(1):5-14. doi: 10.1097/01.pra.0000426323.59698.64.

  PMID: 23334675 DERIVED

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Depressive Disorder; Mood Disorders; Mental Disorders

Results Point of Contact

• Title: Pfizer ClinicalTrials.gov Call Center
• Organization: Pfizer, Inc.

ClinicalTrials.gov_Inquiries@pfizer.com

1-800-718-1021

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: November 25, 2008
• First Posted: November 26, 2008
• Study Start: December 1, 2008
• Primary Completion: April 1, 2010
• Study Completion: April 1, 2010
• Last Updated: June 10, 2011
• Results First Posted: June 6, 2011

Record last verified: 2011-06

Locations

JP (59); US (19)